Altimmune (NASDAQ:ALT) Director Wayne Pisano Purchases 5,000 Shares

Altimmune, Inc. (NASDAQ:ALT) Director Wayne Pisano acquired 5,000 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The stock was acquired at an average cost of $4.08 per share, for a total transaction of $20,400.00. Following the acquisition, the director owned 13,498 shares of the company’s stock, valued at $55,071.84. The trade was a 58.84% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Altimmune Stock Performance

ALT stock traded down $0.06 during midday trading on Friday, reaching $4.02. 3,065,780 shares of the company’s stock traded hands, compared to its average volume of 8,400,127. Altimmune, Inc. has a 52-week low of $2.90 and a 52-week high of $7.73. The stock has a market cap of $419.45 million, a P/E ratio of -3.76 and a beta of 0.04. The company has a current ratio of 17.18, a quick ratio of 17.18 and a debt-to-equity ratio of 0.08. The stock’s 50-day moving average is $4.49 and its 200 day moving average is $4.17.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.08. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative net margin of 419,575.00% and a negative return on equity of 54.79%. As a group, analysts anticipate that Altimmune, Inc. will post -1.35 EPS for the current year.

Institutional Trading of Altimmune

Several institutional investors have recently made changes to their positions in ALT. Vanguard Group Inc. raised its stake in Altimmune by 23.3% during the 3rd quarter. Vanguard Group Inc. now owns 6,373,638 shares of the company’s stock valued at $24,029,000 after purchasing an additional 1,206,514 shares during the period. Two Sigma Investments LP grew its holdings in Altimmune by 356.6% during the 3rd quarter. Two Sigma Investments LP now owns 1,996,848 shares of the company’s stock valued at $7,528,000 after buying an additional 1,559,562 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Altimmune by 13.4% during the second quarter. Geode Capital Management LLC now owns 1,934,880 shares of the company’s stock valued at $7,489,000 after buying an additional 228,995 shares during the last quarter. Federated Hermes Inc. lifted its holdings in shares of Altimmune by 387.7% in the second quarter. Federated Hermes Inc. now owns 915,458 shares of the company’s stock worth $3,543,000 after buying an additional 727,731 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Altimmune by 155.2% in the second quarter. Bank of America Corp DE now owns 716,019 shares of the company’s stock worth $2,771,000 after buying an additional 435,467 shares in the last quarter. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Analyst Ratings Changes

ALT has been the subject of a number of analyst reports. Citigroup restated a “market outperform” rating on shares of Altimmune in a research report on Wednesday, November 12th. Citizens Jmp cut their price objective on Altimmune from $15.00 to $14.00 and set a “market outperform” rating for the company in a research note on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a research note on Monday, December 29th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Altimmune in a report on Monday, October 20th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Altimmune presently has an average rating of “Hold” and a consensus target price of $16.60.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.